Skip to main content
The Journal of Veterinary Medical Science logoLink to The Journal of Veterinary Medical Science
. 2026 Jul 30;88(10):1523–1530. doi: 10.1292/jvms.26-0111

Sedative effects of administration through the nares of dexmedetomidine, midazolam, and butorphanol in cockatiels (Nymphicus hollandicus): a preliminary crossover study

Sakura ISAYAMA 1, Mizuki TANAHASHI 1, Seiko DOI 2, Hitomi FUCHIGAMI 1, Yukiko SASSA-O’BRIEN 3, Satoshi TAKASHIMA 1,*, Sanae SHIBATA 1,2
PMCID: PMC13680717  PMID: 42528181

Abstract

This study evaluated the efficacy and safety of a sedation protocol through the nares combining dexmedetomidine with midazolam and butorphanol in cockatiels. Six adults were enrolled in a randomized, 4 treatment, 4 period crossover trial comparing a control regimen (midazolam 3 mg/kg and butorphanol 3 mg/kg) with three combinations including dexmedetomidine at 0.04, 0.06, or 0.08 mg/kg, administered through the nares. The volume of all treatments was standardized to the volume of the highest dose of dexmedetomidine administered (2 mL/kg) with sterile saline solution. Sedation scores, respiratory rate, heart rate, and cloacal temperature were recorded for 10 min after drug administration and during 15 min of manual restraint, followed by flumazenil and atipamezole via the nares for reversal. All birds completed all treatments; mild sneezing occurred but no clinically relevant respiratory complications were observed. Medium and high dose dexmedetomidine produced higher sedation scores and lower respiratory rate, heart rate, and body temperature during restraint than the control regimen, whereas the control group showed increased respiratory rate, suggesting insufficient suppression of restraint induced stress. In all groups, sedation and physiological variables returned to near baseline values within 15 min after reversal, and no serious adverse events occurred. These findings indicate that administration through the nares dexmedetomidine at 0.06 or 0.08 mg/kg combined with midazolam and butorphanol provides deeper, more stable, and reversible sedation and improved control of stress responses in cockatiels and may represent a clinically useful protocol in this species.

Keywords: cockatiel, dexmedetomidine, sedation via the nares

INTRODUCTION

Restraint of avian patients is often necessary for procedures such as physical examinations, blood sampling, and diagnostic imaging; however, manual restraint itself can be very stressful for birds. Therefore, sedatives are commonly used to reduce the stress caused by restraint and to facilitate the procedures [2]. Sedatives are commonly administered intramuscularly or intranasally [2]. Administration through the nares is convenient and noninvasive because, unlike intramuscular administration, it does not require injections and avoids the risk of hemorrhage in birds with coagulopathies [3]. However, administration through the nares may be associated with drug loss due to sneezing or inadvertent swallowing.

A combination of midazolam and butorphanol is commonly used for sedation in birds [3, 8, 10]. Midazolam is a benzodiazepine with both sedative and anxiolytic properties. Butorphanol is an opioid with both sedative and analgesic properties. In cockatiels (Nymphicus hollandicus), the administration through the nares of midazolam (3 mg/kg) and butorphanol (3 mg/kg) has been shown to induce moderate sedation [3]. However, it was observed that body temperature still increases during restraint, indicating that the ability to respond physiologically to restraint stress remained. Therefore, a more profound sedation method may be needed in cockatiels to improve restraint quality and animal welfare.

Alpha-2 receptor agonists such as dexmedetomidine are not widely used for sedation in birds. Although dexmedetomidine has excellent sedative, analgesic, and muscle-relaxing effects, its selectivity for α2-adrenoceptors may result in respiratory depression and bradycardia. A few studies have explored the administration of dexmedetomidine in birds. In pigeons, administration through the nares of dexmedetomidine (0.08 mg/kg) and midazolam (5 mg/kg) induced moderate sedation, resulting in lower heart and respiratory rates [6]. In a study on budgerigars, intramuscular administration of midazolam (3 mg/kg) and dexmedetomidine (0.04 mg/kg or 0.08 mg/kg) resulted in a dose-dependent sedation effect, accompanied by a reduction in respiration and heart rate [12]. In addition, in a study on zebra and Bengalese finches, intramuscular administration of medetomidine, midazolam, and butorphanol caused breathing with beak clapping, production of sound with breathing, a change in beak color, vomiting, and decreased body temperature [7]. In that study, high doses of medetomidine, midazolam, and butorphanol produced long-lasting deep sedation in zebrafish finches, whereas in Bengalese finches, mortality was significantly higher when high doses of antagonists were not administered. These findings suggest that the effects of α2-receptor agonists vary considerably among bird species.

To our knowledge, no studies have investigated the effects of dexmedetomidine in cockatiels. Given the potential benefits and risks of alpha-2 agonist use in birds, we conducted a pilot study to evaluate the sedative effects of administered dexmedetomidine via the nares at low, medium, and high doses, in combination with midazolam and butorphanol, in cockatiels. This preliminary trial was intended to explore the feasibility, efficacy, and safety of this protocol, and to generate data to guide future, larger-scale studies.

MATERIALS AND METHODS

Animals

Six adult cockatiels (four males and two females) under 5 years of age were used in this study. Their body weight ranged from 102 to 121 g (mean ± standard deviation: 109.9 ± 5.29 g). Hematocrit was measured, white blood cell counts were obtained, and fecal examinations were conducted, and all birds was considered to be in good health. All birds in this study were unaccustomed to handling and restraint. One bird was used repeatedly for four experiments, with a minimum interval of 1 week between experiments. The experimental order for each group was randomly determined using the website Research Randomizer (https://www.randomizer.org; accessed on May 23, 2024).

This study was approved by the Gifu University Animal Experiment Review Committee (no. AG-P-N-20230077).

Sedation protocol

The birds were divided into two groups: one receiving dexmedetomidine (Dexmedetomidine Intravenous Injection 200 μg, Sandoz K.K, Tokyo, Japan), midazolam (Dorumicum Injection 10 mg, Maruishi Pharmaceutical Co., Ltd., Osaka, Japan) 3 mg/kg, and butorphanol (Vetorphale, Meiji Seika Pharma Co., Tokyo, Japan) 3 mg/kg (DMB group), and the other receiving midazolam 3 mg/kg and butorphanol 3 mg/kg. The DMB group was subdivided into three groups according to the dose of dexmedetomidine administered: the low-dose group (LD group) received 0.04 mg/kg; the medium-dose group (MD group) received 0.06 mg/kg; and the high-dose group (HD group) received 0.08 mg/kg. To ensure treatment blinding and uniformity of the drug volume, the volume of all treatments was standardized to the volume of the HD treatment (2 mL/kg) with sterile saline solution (OTSUKA NORMAL SALINE, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). In a pilot study in cockatiels, although some birds sneezed following intranasal administration of 2 mL/kg, we confirmed that no obvious fluid expulsion from the nasal cavities occurred. The cockatiels were placed in transparent plastic cages and observed during the experiments. The birds were manually restrained with their heads tilted upwards and administered sedatives according to one of the four protocols above. Sedatives were administered slowly over a period of one to two min using an insulin syringe (BD Low dose 1/2 mL 29 G × 12.7 mm, Nippon Becton Dickinson Co., Ltd., Tokyo, Japan, or BD Low dose 3/10 mL 30 G × 8 mm, Nippon Becton Dickinson Co., Ltd.) with the needle removed. The medication was dispensed evenly and alternately into the right and left nasal passages to prevent it from being expelled from the nasal cavities. Birds were captured 10 min after administration through the nares and manually restrained for 15 min by gently holding the neck between the index and middle fingers, as is commonly performed in avian clinical practice. At the end of the restraint period, antagonists were administered through the nares to each group: 0.05 mg/kg of flumazenil (Anexate, Nipro Corp., Osaka, Japan) and 0.4 mg/kg of atipamezole (Antisedan, Kyoritsu Seiyaku Corp., Tokyo, Japan) to the LD group; 0.05 mg/kg of flumazenil and 0.6 mg/kg of atipamezole to the MD group; 0.05 mg/kg of flumazenil and 0.8 mg/kg of atipamezole to the HD group; and 0.05 mg/kg of flumazenil to the Control group. Atipamezole was diluted 1:5 with a saline solution to achieve a final concentration of 1 mg/mL. Similar to the sedatives, antagonists were administered slowly over a period of one to two min using an insulin syringe, with the medication being dispensed equally and alternately into the right and left nasal passages to prevent it from being expelled from the nasal cavities.

Evaluation of sedation scores

Sedation scores were evaluated at the following time points: 1 min before administration of the sedation drug (baseline); 2, 4, 6, 8, and 10 min after administration of the sedation drug; every minute for 15 min from the commencement of restraint; and 15 min after the administration of the antagonist drug (i.e., 40 min after the administration of the sedative drug). The sedation scores were obtained using a partially modified version of the sedation scoring system employed in previous studies (Table 1) [3, 9]. The response to visual stimulation was assessed by briefly moving a white towel outside the cage. The response to auditory stimuli was evaluated when the experimenter clapped his hand outside the cage. Responses to tactile stimuli were evaluated by swabbing the dorsal surface of the bird with a cotton swab. The sedation score during the restraint period was evaluated on a scale of 0–2 points based on eye position and intensity of struggle, and the total score (0–4 points) was calculated. Evaluations were conducted by a single assessor who was blinded to the type of sedation used. The first sedation effect was defined as the time at which any change in the eyelid, head, or body position or the onset of ataxia was detected after drug administration.

Table 1. Sedation scoreing system.

Variable Sedation Score

0 1 2
Eye position Open Partially closed Fully closed
Head position Upright Hanging Beak or head resting on floor
Body position Standing Crouched or resting on tibiotarsal-tarsometatarsal joints Sternally recumbent
Visual stimulation Head and eye movement Reduced head or eye movement No response
Auditory stimulation Head and eye movement Reduced head or eye movement No response
Tactile stimulation Head and eye movement Reduced head or eye movement No response
Struggling intensity Strong and repetitive movement of head, body,wings, and hind limbs Reduced strength and frequency of movement of head, body,wings, and hind limbs No movement of head, body, wings, and hind limbs

Sedatiom scoreing system in this study was modified and adapted from previous reports [4, 9].

Measurement of the physiological variables

The respiratory rate was measured at 1, 3, 5, 7, and 9 min after sedative administration. Respiratory rate, heart rate, and body temperature were measured every 3 min during the restraint period. The respiratory rate was measured by observing the chest and abdominal movements, and the heart rate was measured using a stethoscope. Heart rates of >600 beats/min were recorded as 600 beats/min. The body temperature was measured by inserting the lubricating gel-coated probe of a digital thermometer (Digital Thermometer for Animals, DIGIFLASH; Solv Corp., Yokohama, Japan) into the cloaca. All the physiological variables were assessed by the same investigator. After completion of the experiment, the birds were returned to their original cages after confirming that they had recovered from their sedentary state.

Statistical analysis

Statistical software (Statcel5, OMS, Tokyo, Japan) and R ver. 4.4.1 (https://www.r-project.org) was used for statistical analysis. Repeated-measures analysis of variance was used to evaluate physiological parameters for the effects of treatment and time, with Tukey’s method used as a post-test. Friedman’s test was used to compare sedation scores among the groups over time, with the Nemenyi test used as a post-test. The Friedman test was used to compare the first sedation effect among the groups, followed by the Conover test as a post-hoc analysis, with Bonferroni correction. As the body temperature was not measurable at some time points, these birds were excluded from the tests. Statistical significance was set at P<0.05.

RESULTS

Adverse effects following administration through the nares

Sneezing was observed during and after administration through the nares of the drug in eight of the 24 experiments. Four experiments were conducted per bird, and all birds sneezed in at least one experiment. However, no birds were observed to have expelled the medication from their nasal cavities into the environment through sneezing, and no respiratory symptoms or other adverse effects of administration through the nares were observed in any bird.

Onset of sedative effects

The median (interquartile range) time for the first sedation effect was 115 sec (50–150 sec) in the Control group, 75 sec (30–100 sec) in the LD group, 40 sec (30–140 sec) in the MD group, and 53 sec (30–120 sec) in the HD group. A trend toward an earlier onset of the effect in the HD and MD groups than in the Control group was noted (P=0.066 and P=0.050, respectively).

Evaluation of sedative score

Sedation scores were higher in the HD than in the Control group at 4, 6, 8, and 10 min after administration (P<0.05) (Table 2). In the Control group, the sedation scores were higher at 8 and 10 min after sedation than before sedation (P<0.05) (Table 2). In the LD and HD groups, the sedation scores were higher at 6, 8, and 10 min after sedation than before sedation (P<0.05) (Table 2). In the MD group, the sedation scores were higher at 4, 6, 8, and 10 min after sedation than before sedation (P<0.05) (Table 2). Sedation scores were higher at 10 min after sedation in the LD and MD groups and at 6, 8, and 10 min after sedation in the HD group than at 15 min after antagonist administration (P<0.05) (Table 2). Compared with the Control group, sedation scores were higher in the HD group at 5, 10, and 11 min of restraint and in the MD group at 6 min of restraint (P<0.05) (Table 3).

Table 2. Sedation scores for six cockatiels after the administration through the nares of drug combinations and 15 min after reversal of sedation.

Group Time after dexmedetomidine-midazolam-butorphanol or midazolam-butorphanol administration (min)

−1 2 4 6 8 10 40

(Baseline) (15 min after reversal agent administration)
Control 0 (0–0) 3 (0–7) 5.5 (1–8) 6.5 (0–9) 7 (3–9)† 7.5 (3–10)† 2 (0–5)
LD 0 (0–0) 3 (1–6) 7.5 (4–9) 8 (7–9)† 8.5 (7–10)† 9 (8–10)†‡ 1 (0–5)
MD 0 (0–0) 4.5 (1–7) 8.5 (6–9)† 8 (7–10)† 8 (7–10)† 8.5 (8–10)†‡ 3.5 (1–5)
HD 0 (0–0) 4 (1–7) 9 (5–10)* 9.5 (8–10)*†‡ 9.5 (8–10)*†‡ 10 (9–11)*†‡ 0.5 (0–3)

Values are presented as the median (range). LD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.04 mg/kg dexmedetomidine, MD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.06 mg/kg dexmedetomidine, HD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.08 mg/kg dexmedetomidine, Control: 3 mg/kg midazolam and 3 mg/kg butorphanol only. Reversal treatment consisted of 0.05 mg/kg flumazenil combined with 0.4 mg/kg atipamezole in the LD, 0.6 mg/kg atipamezole in the MD, and 0.8 mg/kg atipamezole in the HD, whereas only 0.05 mg/kg flumazenil was administered in the Control. *: P<0.05 (compared with the control group at the same time point). †: P<0.05 (compared with the baseline of the same group). ‡: P<0.05 (compared with 15 min after reversal agent administration in the same group).

Table 3. Sedation scores for six cockatiels during a 15-min period of manual restraint after the administration through the nares.

Group Time during restraint (min)

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Control 1 2 2.5 2.5 2 2 2 2.5 2 2 2 2.5 2.5 3 2.5 2.5
(1–2) (0–3) (0–3) (0–4) (0–4) (1–3) (0–3) (0–4) (0–4) (1–4) (1–3) (1–3) (1–4) (1–4) (2–4) (1–4)
LD 1.5 2 2 3 3.5 3.5 4 4 3.5 3.5 4 4 3.5 4 3.5 4
(0–3) (1–4) (1–4) (1–4) (1–4) (0–4) (2–4) (2–4) (2–4) (2–4) (2–4) (2–4) (2–4) (2–4) (2–4) (3–4)
MD 0.5 2 3 3.5 3.5 4 4 * 3.5 4 4 4 4 4 4 4 4
(0–2) (1–4) (2–4) (2–4) (2–4) (2–4) (2–4) (2–4) (3–4) (2–4) (3–4) (2–4) (4–4) (2–4) (4–4) (3–4)
HD 2 2.5 3.5 4 4 4 * 3.5 4 4 4 4* 4* 4 4 4 4
(1–4) (1–4) (1–4) (2–4) (2–4) (3–4) (3–4) (2–4) (3–4) (4–4) (3–4) (4–4) (4–4) (4–4) (3–4) (3–4)

Values are presented as the median (range). LD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.04 mg/kg dexmedetomidine, MD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.06 mg/kg dexmedetomidine, HD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.08 mg/kg dexmedetomidine, Control: 3 mg/kg midazolam and 3 mg/kg butorphanol only. Reversal treatment consisted of 0.05 mg/kg flumazenil combined with 0.4 mg/kg atipamezole in the LD, 0.6 mg/kg atipamezole in the MD, and 0.8 mg/kg atipamezole in the HD, whereas only 0.05 mg/kg flumazenil was administered in the Control. *: P<0.05 (compared with the Control at the same time point).

Respiratory rate in sedation

Compared with the Control group, the respiratory rate was lower in the MD and HD groups at all time points during restraint, and were lower in the LD group at 6, 12, and 15 min of restraint (P<0.05) (Table 4). No significant differences were noted among the groups in the period from sedative administration to the onset of restraint or at 15 min after antagonism (Table 4). The respiratory rate in the Control group was higher at 12 and 15 min of restraint than at 5, 7, and 9 min of sedation (P<0.05) (Table 4). The respiratory rate in the HD group was lower at all time points after sedation and during restraint than at 15 min after antagonist administration (P<0.05) (Table 4). No significant differences were observed between the LD and MD groups over time.

Table 4. Respiratory rates (mean ± SEM) in six cockatiels after sedative administration through the nares including a 15-min restraint period and 15 min after reversal of sedation.

Group Time after sedative administration (min)

1 3 5 7 9
Control 60 ± 6.6 57 ± 6.8 54 ± 4.6 54 ± 6.7 53 ± 7.3
LD 70 ± 22 53 ± 9.0 47 ± 9.0 40 ± 4.0 40 ± 3.0
MD 46 ± 5.1 40 ± 3.8 36 ± 3.2 36 ± 5.4 39 ± 6.3
HD 47 ± 4.2‡ 41 ± 3.3‡ 41 ± 4.5‡ 41 ± 4.2‡ 38 ± 5.1‡

Group Time during restraint (min) 15 min after reversal agent administration

0 3 6 9 12 15

Control 104 ± 12 104 ± 11 108 ± 12 97 ± 14 111 ± 18† 112 ± 19† 91 ± 6.8
LD 74 ± 6.3 68 ± 13 53 ± 12* 55 ± 6.3 52 ± 9.0* 50 ± 6.0* 83 ± 6.6
MD 63 ± 7.9* 51 ± 11* 42 ± 8.6* 53 ± 13* 46 ± 10* 50 ± 12* 75 ± 7.8
HD 49 ± 7.7*‡ 39 ± 8.3*‡ 38 ± 7.2*‡ 37 ± 5.0*‡ 34 ± 3.5*‡ 32 ± 3.2*‡ 90 ± 7.4

LD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.04 mg/kg dexmedetomidine, MD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.06 mg/kg dexmedetomidine, HD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.08 mg/kg dexmedetomidine, Control: 3 mg/kg midazolam and 3 mg/kg butorphanol only. Reversal treatment consisted of 0.05 mg/kg flumazenil combined with 0.4 mg/kg atipamezole in the LD, 0.6 mg/kg atipamezole in the MD, and 0.8 mg/kg atipamezole in the HD, whereas only 0.05 mg/kg flumazenil was administered in the Control. *: P<0.05 (compared with the control group at the same time point). †: P<0.05 (compared with 5, 7, and 9 min after sedative administration in the Control). ‡: P<0.05 (compared with 15 min after reversal agent administration in the same group).

Heart rate in sedation

The heart rate was lower in the LD, MD, and HD groups at all time points during restraint than in the Control group (P<0.05) (Table 5). Heart rates were lower in the MD and HD groups than in the LD group at 9 and 12 min of restraint (P<0.05) (Table 5). No significant differences were seen among the groups at 15 min after antagonist administration. One bird in the HD group developed an arrhythmia that appeared to be of respiratory origin. The heart rates of the LD, MD, and HD groups were lower at all time points during restraint than at 15 min after antagonist administration (P<0.05) (Table 5). The MD group showed lower heart rates at 3, 6, 9, 12, and 15 min than at 0 min of restraint (P<0.05) (Table 5). No significant differences were observed across time points in the Control group.

Table 5. Heart rates (mean ± SEM) in six cockatiels during a 15-min period of manual restraint after sedative administration through the nares and 15 min after reversal of sedation.

Group Time during restraint (min) 15 min after reversal agent administration

0 3 6 9 12 15
Control 564 ± 20 563 ± 20 558 ± 19 578 ± 15 557 ± 22 539 ± 24 568 ± 21
LD 354 ± 29*‡ 318 ± 43*‡ 268 ± 58*‡ 304 ± 43*‡ 252 ± 29*‡ 239 ± 31*‡ 544 ± 19
MD 345 ± 39*‡ 242 ± 23*‡§ 213 ± 17*‡§ 197 ± 13*†‡§ 168 ± 16*†‡§ 190 ± 20*‡§ 572 ± 14
HD 270± 43*‡ 23 ±31*‡ 196 ± 22*‡ 177 ± 18*†‡ 165 ± 11*†‡ 195 ± 26*‡ 564 ± 27

LD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.04 mg/kg dexmedetomidine, MD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.06 mg/kg dexmedetomidine, HD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.08 mg/kg dexmedetomidine, Control: 3 mg/kg midazolam and 3 mg/kg butorphanol only. Reversal treatment consisted of 0.05 mg/kg flumazenil combined with 0.4 mg/kg atipamezole in the LD, 0.6 mg/kg atipamezole in the MD, and 0.8 mg/kg atipamezole in the HD, whereas only 0.05 mg/kg flumazenil was administered in the Control. *: P<0.05 (compared with the control group at the same time point). †: P<0.05 (compared with the LD at the same time point). ‡: P<0.05 (compared with 15 min after reversal agent administration in the same group).

Body temperature in sedation

One bird each in the Control and LD groups struggled strongly against restraint for 3 min, which precluded temperature measurement. Compared to the Control group, the MD and HD groups had lower temperatures at all time points during restraint, and the LD group had lower temperatures at 3, 6, 9, 12, and 15 min of restraint (P<0.05) (Table 6). No significant differences were present among the groups at 15 min after antagonist administration. Body temperatures in the LD and HD groups were lower at 3, 6, 9, 12, and 15 min of restraint than at 15 min after antagonist administration (P<0.05) (Table 6). Body temperature in the MD group was lower at 9, 12, and 15 min of restraint than at 15 min after antagonist administration (P<0.05) (Table 6). Body temperatures of the LD, MD, and HD groups were lower at 12 min of restraint than at 0 min of restraint (P<0.05) (Table 6). In addition, the temperatures of the MD and HD groups were lower at 15 min than at 0 min of restraint (P<0.05) (Table 6). No significant differences were observed across restraint time points in the Control group.

Table 6. Body temperatures (mean ± SEM) in six cockatiels during a 15-min period of manual restraint after sedative administration through the nares and 15 min after reversal of sedation.

Group Time during restraint (min) 15 min after reversal agent administration

0 3 6 9 12 15
Control 41.4 ± 0.30 41.6 ± 0.12 41.2 ± 0.26 41.3 ± 0.23 41.2 ± 0.22 41.1 ± 0.22 41.2 ± 0.21
LD 40.7 ± 0.16 40.4 ± 0.20† 40.4 ± 0.20*† 40.1 ± 0.22*† 39.7 ± 0.27*†‡ 39.7 ± 0.34*† 41.1 ± 0.37
MD 40.4 ± 0.06* 40.2 ± 0.07* 40.0 ± 0.07* 39.9 ± 0.13*† 39.6 ± 0.18*†‡ 39.4 ± 0.22*†‡ 40.6 ± 0.21
HD 40.3 ± 0.16* 40.1 ± 0.18*† 39.8 ± 0.22*† 39.4 ± 0.23*† 39.2 ± 0.21*†‡ 39.0 ± 0.20*†‡ 41.1 ± 0.33

LD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.04 mg/kg dexmedetomidine, MD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.06 mg/kg dexmedetomidine, HD: 3 mg/kg midazolam and 3 mg/kg butorphanol combined with 0.08 mg/kg dexmedetomidine, Control: 3 mg/kg midazolam and 3 mg/kg butorphanol only. Reversal treatment consisted of 0.05 mg/kg flumazenil combined with 0.4 mg/kg atipamezole in the LD, 0.6 mg/kg atipamezole in the MD, and 0.8 mg/kg atipamezole in the HD, whereas only 0.05 mg/kg flumazenil was administered in the Control. *: P<0.05 (compared with the control group at the same time point). †: P<0.05 (compared with 15 min after reversal agent administration in the same group). ‡: P<0.05 (compared with 0 min of restraint in the same group).

DISCUSSION

This study demonstrated the influence of dexmedetomidine co-administration with midazolam and butorphanol on the sedation effects, physiological parameters, and safety in cockatiels. No adverse respiratory effect of the co-administration was observed. Sedation scores were significantly higher with higher doses of dexmedetomidine. Respiratory rate, heart rate, and body temperature were lower in dexmedetomidine-treated groups, whereas the respiratory rate increased during restraint compared to pre-restraint levels in the Control group that received only midazolam and butorphanol. Body temperature declined over time in the dexmedetomidine-treated groups, but all parameters returned to baseline within 15 min after antagonist administration.

Onset of sedation was rapidly observed in the MD and HD groups. This suggests that co-administration of dexmedetomidine may accelerate the onset of sedation. In this study, onset of sedation effect in the Control group was noted at 115 sec (50–150 sec), consistent with the findings of a previous study in cockatiels [3] that reported sedation effects at 90 sec (45–180 sec) after administration through the nares of midazolam and butorphanol at the same doses as used in this study. Previous studies on sedative administration through the nares in budgerigars, pigeons, and ostriches have reported faster onset times with midazolam than with diazepam or xylazine alone [1, 11, 13]. Furthermore, studies on administration through the nares of sedatives in ring-necked parakeets showed faster onset times with midazolam or detomidine alone than with xylazine alone [14]. In contrast, a study on sedative administration through the nares in canaries reported that onset time was slower with detomidine than with diazepam, midazolam, and xylazine, although no significant differences were observed among the four groups [15]. These studies suggested that differences in sedation onset time due to the type of sedation vary among bird species, with midazolam tending to exhibit relatively rapid effects in many bird species. However, to the authors’ knowledge, no studies have compared sedation onset times in birds when midazolam or butorphanol was co-administered with α2-adrenergic receptor agonists. Thus, the observed shortening of onset time with dexmedetomidine co-administration in this study represents a novel finding, indicating the need for further research on the effects of α2-adrenergic receptor agonist co-administration on sedation onset in birds.

The MD and HD groups exhibited higher sedation scores at multiple time points than those in the Control group, demonstrating that dexmedetomidine co-administration produces deeper sedation. Additionally, regarding the temporal changes in sedation scores within the first 10 min after drug administration, the Control group showed elevated scores from 8-min post-administration as compared to baseline. In contrast, the LD and HD groups showed increased scores at 6-min post-administration, whereas the MD group showed increased scores at 4-min post-administration. These findings are consistent with the shortened onset times observed in the MD and HD groups, suggesting that the co-administration of dexmedetomidine may have contributed to these results. However, as the effects on the onset time and sedation scores in the LD group were unclear, further investigation is warranted.

Regarding changes in physiological parameters, the Control group exhibited higher respiratory rates during restraint than prior to restraint. This finding was consistent with that of a previous study, in which midazolam administration through the nares in Hispaniolan Amazon parrots was associated with increased respiratory rates during restraint [9]. Additionally, a previous study of cockatiels reported elevated respiratory rates during restraint in groups not administered sedatives [3]. In another study on red-tailed hawks, the use of a hood during restraint was shown to reduce respiratory rates as compared to restraint without a hood [4]. These findings suggested that the increased respiratory rate observed during restraint was a stress-induced response. In this study, the increase in respiratory rate observed during restraint in the Control group may have been caused by the insufficient sedative effects of midazolam and butorphanol, leading to a stress response. The respiratory rates in the DMB groups overall during restraint were lower than those in the Control group, suggesting that the sedative effects of dexmedetomidine co-administration may have mitigated the stress-induced respiratory rate increase. Notably, the LD group showed lower respiratory rates than those of the Control group at certain time points, despite the lack of significant differences in sedation scores between the two groups. Furthermore, while the baseline respiratory rate in birds weighing 100–200 g has been reported to range from 35 to 50 breaths/min [5, 14], some individuals in the MD and HD groups exhibited respiratory rates below this range (24 breaths/min). These findings suggest that the observed decrease in respiratory rate in the DMB groups may have been attributable not only to dexmedetomidine-induced alleviation of restraint stress, but also to its potential respiratory depressant effects.

The observed decrease in heart rate in the DMB groups is thought to be due to the α2-adrenergic receptor action of dexmedetomidine. Moreover, because the MD and HD groups had lower heart rates than that of the LD group at multiple time points, dexmedetomidine was considered to induce dose-dependent bradycardia. A study on budgerigars reported that the intramuscular administration of midazolam combined with either a high or low dose of dexmedetomidine did not result in significant differences among the groups [12]. However, the HD group exhibited an average heart rate reduction of less than 20% as compared with the LD group. In the present study, although perfusion, oxygenation, and blood pressure were not evaluated, no complications associated with heart rate reduction were observed, except in one patient who exhibited respiratory arrhythmia. Bradycardia resolved within 15 min after the administration of the reversal agent, and all birds remained healthy after the experiment. These findings indicated that bradycardia induced by dexmedetomidine can be immediately reversed by atipamezole administration, without causing severe adverse effects.

Body temperature was lower in the DMB groups than in the Control group and showed a decreasing trend over time. Similarly, a previous study on administration through the nares of midazolam and dexmedetomidine in pigeons reported a decrease in body temperature [6]. In contrast, a study on the administration through the nares of midazolam and butorphanol in cockatiels at the same doses reported an increase in body temperature during restraint [3]. Although no changes in body temperature during restraint were observed in the Control group in this study, which contrasts with previous findings, it is possible that the insufficient sedative effects in the previous study failed to suppress the stress response, resulting in a temperature increase. In this study, although no temperature increase was observed, the elevated respiratory rate during restraint suggests that the sedative effects were insufficient. These findings indicate that the doses of midazolam and butorphanol used in this and previous studies were inadequate to eliminate the stress response during restraint.

Sneezing was observed during and after sedative administration. The volume of the drug solution used in a previous study on administration through the nares of drugs in cockatiels was 1 mL/kg, and no sneezing was reported [3]. Previous studies have used volumes of 1.46 mL/kg in ring-necked parakeets, approximately 2.7 mL/kg in canaries, and approximately 2.8 mL/kg in budgerigars, with no sneezing reported [13,14,15]. In this study, the solution volume was 2 mL/kg, which might have been excessive for the cockatiels. These findings suggest that the tolerable volume of administered drug solutions via the nares varies among bird species, highlighting the need to determine the appropriate volume for cockatiels. Nevertheless, no respiratory symptoms or adverse effects were observed.

In all groups, sedation was reversed within 15 min after administration of the reversal agent, with heart rate, respiratory rate, and body temperature returning to similar levels across all groups. Thus, the sedation protocol used in this study was reversible and clinically useful. However, because the reversal agent was administered 25 min after sedative administration in this study, the exact duration of the sedative effects was not determined. Previous studies on the duration of sedative effects in budgerigars, pigeons, and ring-necked parakeets have consistently reported that the use of α2-adrenergic receptor agonists, such as xylazine or detomidine alone, extends the duration of sedative effects as compared to benzodiazepines alone [11, 13, 14]. It is likely that the co-administration of sedatives extends the duration of the effects in cockatiels. Further studies are needed to investigate the duration of sedative effects when benzodiazepines are combined with α2-adrenergic receptor agonists.

While favorable sedation has been achieved in budgerigars and pigeons with midazolam and dexmedetomidine administration, a prior study on intramuscular administration of medetomidine, midazolam, and butorphanol in Bengalese finches reported numerous adverse effects and high mortality rates [6, 7, 12]. In this study, no severe adverse effects or mortality were observed following the intranasal administration of dexmedetomidine, midazolam, or butorphanol in cockatiels, suggesting the applicability of dexmedetomidine in this species. These findings highlight interspecies differences in the effects of α2-adrenergic receptor agonists, warranting further research on species-specific responses.

This study has inherent limitations, including a small sample size, which restricts statistical power and generalizability. As such, the findings should be interpreted as preliminary and hypothesis-generating rather than confirmatory. In addition, sedation scores were assessed at 2-min intervals following the administration of sedative over a period of one to two min. Although this approach allowed evaluation of time-to-onset of sedation, it is possible that the variability in the duration from the onset to the end of sedation and the frequent scoring procedures may have interfered with the smooth induction of sedation. Moreover, although volume and surface area of the nasal cavity were not evaluated in the present study, the volumes of the solutions administered were tolerated well by the cockatiels. It is possible that a portion of the administered sedative was swallowed or entered the glottis during administration, and that absorption through routes other than the nasal cavity may have contributed to the observed effects. Therefore, the observed effects may not be attributable solely to intranasal absorption.

In conclusion, this exploratory study demonstrated that administration through the nares of dexmedetomidine (0.06 mg/kg or 0.08 mg/kg), in addition to midazolam (3 mg/kg) and butorphanol (3 mg/kg), resulted in deeper and more stable sedation in healthy cockatiels than did the administration of midazolam (3 mg/kg) and butorphanol (3 mg/kg) alone. Furthermore, the co-administration of dexmedetomidine was associated with a decrease in heart rate, respiratory rate, and body temperature. These effects, including sedation, bradycardia, decreased respiratory rate, and hypothermia, were immediately reversed by atipamezole administration. These findings suggest that a combination of midazolam, butorphanol, and dexmedetomidine may be clinically useful in sedating cockatiels.

Conflicts of Interest

The authors declare that there were no conflicts of interest.

Acknowledgments

The authors thank Dr. Shotaro Nagahama, a visiting professor in the Department of Clinical Sciences at the Faculty of Applied Biological Sciences, Gifu University, and the president of the Japanese Association of Veterinary Anesthesiologists, for his invaluable support in planning this research. This research was supported by JSPS KAKENHI, Grant Number 23K05533 (Grant-in-Aid for Scientific Research (C)). The authors received funding from the principal investigator, Dr. Yukiko O’Brien (Tokyo University of Agriculture and Technology).

REFERENCES

  • 1.Araghi M, Azizi S, Vesal N, Dalir-Naghade B. 2016. Evaluation of the sedative effects of diazepam, midazolam, and xylazine after intranasal administration in juvenile ostriches (Struthio camelus). J Avian Med Surg 30: 221–226. doi: 10.1647/2015-110 [DOI] [PubMed] [Google Scholar]
  • 2.Doss G, Mans C. 2021. Avian sedation. J Avian Med Surg 35: 253–268. doi: 10.1647/20-00045 [DOI] [PubMed] [Google Scholar]
  • 3.Doss GA, Fink DM, Mans C. 2018. Assessment of sedation after intranasal administration of midazolam and midazolam-butorphanol in cockatiels (Nymphicus hollandicus). Am J Vet Res 79: 1246–1252. doi: 10.2460/ajvr.79.12.1246 [DOI] [PubMed] [Google Scholar]
  • 4.Doss GA, Mans C. 2016. Changes in physiologic parameters and effects of hooding in red-tailed hawks (Buteo jamaicensis) during manual restraint. J Avian Med Surg 30: 127–132. doi: 10.1647/2015-096 [DOI] [PubMed] [Google Scholar]
  • 5.Forbes NA. 1996. Respiratory problems. pp. 147–157. In: Manual of Psittacine Birds (Forbes NA, Lawton MPC eds.), British Small Animal Veterinary Association, Cheltenham. [Google Scholar]
  • 6.Hornak S, Liptak T, Ledecky V, Hromada R, Bilek J, Mazensky D, Petrovic V. 2015. A preliminary trial of the sedation induced by intranasal administration of midazolam alone or in combination with dexmedetomidine and reversal by atipamezole for a short-term immobilization in pigeons. Vet Anaesth Analg 42: 192–196. doi: 10.1111/vaa.12187 [DOI] [PubMed] [Google Scholar]
  • 7.Ikebuchi M, Okanoya K, Bischof HJ. 2020. Different reactions of zebra finches and Bengalese finches to a three-component mixture of anesthetics. Zool Sci 37: 159–167. doi: 10.2108/zs190055 [DOI] [PubMed] [Google Scholar]
  • 8.Mans C. 2014. Sedation of pet birds. J Exot Pet Med 23: 152–157. doi: 10.1053/j.jepm.2014.02.009 [DOI] [Google Scholar]
  • 9.Mans C, Guzman DS, Lahner LL, Paul-Murphy J, Sladky KK. 2012. Sedation and physiologic response to manual restraint after intranasal administration of midazolam in Hispaniolan Amazon parrots (Amazona ventralis). J Avian Med Surg 26: 130–139. doi: 10.1647/2011-037R.1 [DOI] [PubMed] [Google Scholar]
  • 10.Martel A, Doss GA, Mans C. 2021. Evaluation of the effects of intramuscular injection volume on midazolam-butorphanol-induced sedation in domestic pigeons (Columba livia). J Exot Pet Med 37: 3–7. doi: 10.1053/j.jepm.2021.01.003 [DOI] [Google Scholar]
  • 11.Moghaddam ZA, Sadegh AB, Sharifi S, et al. 2009. Comparison of intranasal administration of diazepam, midazolam and xylazine in pigeons: clinical evaluation. Iran J Vet Sci Technol 1: 19–26. [Google Scholar]
  • 12.Mumm LE, Mans C. 2022. Evaluation of dexmedetomidine-midazolam sedation in budgerigars (Melopsittacus undulatus). J Am Vet Med Assoc 260: 1194–1199. doi: 10.2460/javma.22.01.0005 [DOI] [PubMed] [Google Scholar]
  • 13.Sadegh AB. 2013. Comparison of intranasal administration of xylazine, diazepam, and midazolam in budgerigars (Melopsittacus undulatus): clinical evaluation. J Zoo Wildl Med 44: 241–244. doi: 10.1638/2009-0116R3.1 [DOI] [PubMed] [Google Scholar]
  • 14.Vesal N, Eskandari MH. 2006. Sedative effects of midazolam and xylazine with or without ketamine and detomidine alone following intranasal administration in Ring-necked Parakeets. J Am Vet Med Assoc 228: 383–388. doi: 10.2460/javma.228.3.383 [DOI] [PubMed] [Google Scholar]
  • 15.Vesal N, Zare P. 2006. Clinical evaluation of intranasal benzodiazepines, alpha-agonists and their antagonists in canaries. Vet Anaesth Analg 33: 143–148. doi: 10.1111/j.1467-2995.2005.00244.x [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Veterinary Medical Science are provided here courtesy of Japanese Society of Veterinary Science

RESOURCES